An Overview of the Clinical Efficacy and Safety of Tissue Selective Estrogen Complex: From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials / 고신대학교의과대학학술지
Kosin Medical Journal
;
: 5-16, 2017.
Artigo
em Inglês
| WPRIM
| ID: wpr-149286
ABSTRACT
Hormone therapy (HT) is the most effective treatment for menopausal symptoms, and reduces both spinal and non-spinal postmenopausal osteoporotic fractures. However, a Women's Health Initiative (WHI) trial revealed that progestin-containing HT is associated with higher incidences of breast cancer and coronary heart disease than those associated with placebo. Tissue selective estrogen complex (TSEC) is a novel progestin-free HT option composed of conjugated estrogens (CE) and a selective estrogen receptor modulator. CE at a dose of 0.45 mg combined with 20 mg of bazedoxifene was the first TSEC medication approved in the United States and Korea for women with moderate to severe menopause-related vasomotor symptoms (VMS) and for preventing postmenopausal osteoporosis. This review summarizes the clinical efficacy, safety, and tolerability of TSEC as obtained from the five SMART clinical trials.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Estados Unidos
/
Neoplasias da Mama
/
Menopausa
/
Osteoporose Pós-Menopausa
/
Incidência
/
Saúde da Mulher
/
Resultado do Tratamento
/
Estrogênios Conjugados (USP)
/
Doença das Coronárias
/
Moduladores Seletivos de Receptor Estrogênico
Tipo de estudo:
Ensaio Clínico Controlado
/
Estudo de incidência
/
Estudo prognóstico
Limite:
Feminino
/
Humanos
País/Região como assunto:
América do Norte
/
Ásia
Idioma:
Inglês
Revista:
Kosin Medical Journal
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS